Varenicline - a partial agonist of various subtypes of nicotinic acetylcholine receptors used for the treatment of nicotine addiction. It produces less effect of dopamine release than nicotine and its competitive binding reduces the ability of nicotine to bind, therefore reduces craving and pleasurable effect of nicotine. A report suggest it does not increase side effects such as higher risk to heart attack, or risk of depression or self-harm.
















